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Background: To eliminate visceral leishmaniasis (VL) in India and Nepal, challenges of VL diagnosis, treatment and
reporting need to be identified. Recent data indicate that VL is underreported and patients face delays when
seeking treatment. Moreover, VL surveillance data might not reach health authorities on time. This study quantifies
delays for VL diagnosis and treatment, and analyses the duration of VL reporting from district to central health
authorities in India and Nepal.
Methods: A cross-sectional study conducted in 12 districts of Terai region, Nepal, and 9 districts of Bihar State, India,
in 2012. Patients were interviewed in hospitals or at home using a structured questionnaire, health managers were
interviewed at their work place using a semi-structured questionnaire and in-depth interviews were conducted with
central level health managers. Reporting formats were evaluated. Data was analyzed using two-tailed Mann-Whitney U
or Fisher’s exact test.
Results: 92 VL patients having experienced 103 VL episodes and 49 district health managers were interviewed. Patients
waited in Nepal 30 days (CI 18-42) before seeking health care, 3.75 times longer than in Bihar (8d; CI 4-12). Conversely,
the lag time from seeking health care to receiving a VL diagnosis was 3.6x longer in Bihar (90d; CI 68-113) compared to
Nepal (25d; CI 13-38). The time span between diagnosis and treatment was short in both countries. VL reporting time
was in Nepal 19 days for sentinel sites and 76 days for “District Public Health Offices (DPHOs)”. In Bihar it was 28 days
for “District Malaria Offices”. In Nepal, 73% of health managers entered data into computers compared to 16% in Bihar.
In both countries reporting was mainly paper based and standardized formats were rarely used.
Conclusions: To decrease the delay between onset of symptoms and getting a proper diagnosis and treatment the
approaches in the two countries vary: In Nepal health education for seeking early treatment are needed while in Bihar
the use of private and non-formal practitioners has to be discouraged. Reinforcement of VL sentinel reporting in Bihar,
reorganization of DPHOs in Nepal, introduction of standardized reporting formats and electronic reporting should be
conducted in both countries.
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Visceral leishmaniasis (VL) is a major public health
problem in India and Nepal where it mainly affects the
poor populations of rural areas. In Nepal the disease is
endemic in twelve southern districts with an estimated
population of 5.5 million people at risk. In India VL oc-
curs in 52 districts in the north-east of the country,
mainly in the state of Bihar, in Jharkand and West Bengal.
VL is also endemic in Bangladesh. More than 66% of the
world’s VL cases are found in these three countries where
around 147 million people are at risk of the disease and
40,000 VL cases are registered per year [1-3]. These figures
may underestimate the true burden of disease as VL is
drastically under-reported in the region [4,5]. Active case
detection revealed that the annual VL incidence per
100,000 population ranges from 43-90 cases in Nepal to
298-380 cases in Bihar, India [6,7]. Lately, there have been
important advances in the diagnostics and treatment of
VL, such as the development of rK39 dipstick test and the
oral drug miltefosine [8-10]. Other novel treatment op-
tions include liposomal amphotericin B and paromomycin
as well as combination therapies [10,11].
In 2005, the governments of Nepal, India and
Bangladesh and the WHO committed to eliminate VL
which requires to decrease VL incidence below 10 per
100,000 population by 2015 and Post Kala-Azar Dermal
Leishmaniasis (PKDL) incidence to 0 by 2018 [9]. To
achieve VL elimination, the following areas were to be
strengthened: 1) Early Diagnosis and Complete Case
Management, 2) Integrated Vector Management and
Vector Surveillance, 3) Effective Disease Surveillance
through Passive and Active Case Detection (ACD) and
Vector Surveillance, 4) Social Mobilization and Building
Partnerships, 5) Clinical and Operational Research.
A challenge for early VL diagnosis remains the trad-
itional health care seeking behavior of patients who
often first consult unqualified private doctors, quacks,
indigenous healers or local chemists [7]. Furthermore,
VL diagnosis can be delayed because patients remain at
home for economic and social constraints despite feeling
sick [12]. As community mobilization and awareness
raising has been performed in Nepal and India, people
might seek health care faster after onset of VL symp-
toms now. An additional challenge for early VL case
diagnosis is the lack of appropriately equipped health fa-
cilities to rural patients [7]. In India, the first level of the
health care system is constituted by so-called Sub-
Centers whereas in Nepal, Sub-health Posts and Health
Posts are in use. All first level institutions do not diag-
nose or treat VL. Primary Health Centers (PHCs) and
Community Health Center, secondary level health care
institutions diagnose and treat VL in India whereas
PHCs in Nepal do not. District hospitals (DHs) perform
diagnosis and treatment of VL in both countries but areusually located in the district capital only. Many patients
report to near public providers or, mainly in India, to
private providers first and then require referral to public
services which are capable of VL diagnosis or, in India,
to specialized private diagnostic laboratories. This re-
quires well-trained health workers and also implies long
travel times for patients.
To be able to perform ACD in localities where a new
case has been reported, a fast and reliable VL surveil-
lance system is required. However, there is currently a
gap between estimated and reported cases [6,13,14]. In
India, VL surveillance is complex as patients are treated
by private as well as public health providers and cases
treated in private facilities are not reported to the gov-
ernment system. Furthermore, it is currently unclear in
both countries how fast and by what means information
on diagnosed and hospitalized cases is transferred to
higher health authorities.
Briefly, the surveillance system in Nepal requires dis-
trict hospitals to prepare a standardized hard-copy re-
port and sent it to the District Public Health Office
(D(P)HO). The D(P)HO is then obliged to compile a
joint report for the Epidemiology and Disease Control
Division (EDCD) in Kathmandu which can then prepare
an adequate public health response. In addition, the
Early Warning and Reporting System (EWARS), an elec-
tronic hospital-based sentinel surveillance system estab-
lished in some districts in Nepal in 1996 [15], can
provide timely information to central level decision
makers. The 40 EWARS sites currently monitor VL and
five other communicable diseases [16]; however, it is un-
clear how EWARS information currently contributes to
VL elimination measures (Figure 1).
In Bihar PHCs and district hospitals prepare a stan-
dardized hard-copy report and sent it to the District
Malaria Offices (DMOs). DMOs then compile the dis-
trict report and submit it to the State Program Office
Kala-Azar (SPOKA) who again forwards a compiled
monthly VL state report to the National Vector Borne
Disease Control Program (NVBDCP) in Delhi. The
NVBDCP is the final authority for VL programs (Figure 1).
This study analyzes the time VL patients wait after on-
set of symptoms until they seek help and how much
time is then required until they receive a diagnosis and
treatment. Furthermore, the study identifies how long it
takes to send the patient’s report from the district to the
center and describes the implications of these lags for
the VL elimination program.
Methods
Study design
This study compares the VL reporting systems of two
VL endemic regions, Bihar state in India and Terai re-
gion in Nepal, and quantifies the delay VL patients
Figure 1 Flow chart of VL reporting systems in Nepal and India. The standard hierarchical way of VL reporting from district level to state/
national level is depicted with red arrows. Alternative reporting strands are depicted with black arrows. The time of VL case reporting from district
to center, TR, was recorded for the standard as well as for alternative reporting strands. In Nepal, VL case information from HMIS is used by ECDC.
In Bihar/India, HMIS does not provide VL case information to SMO. In Nepal, EWARS sites conduct VL sentinel reporting whereas in India no VL
sentinel sites were active. Abbreviations used in this figure can be found in the text or the list of abbreviations.
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nosis and receiving treatment. It was designed as a
cross-sectional study using structured and semi-structured
questionnaires. Data was collected from July to September
2012. VL endemic regions in Terai, Nepal, and Bihar,
India, are adjacent and possess a similar geography and
population. This allows for a focused comparison of VL
reporting systems, health system performance and patient
behavior.
Study population – patient; Nepal
VL patients were identified in hospitals of different
Nepali and Bihari districts. Patients were selected on
the basis of their availability at times of the field visit
as well as their current health status. Patients were
interviewed with the help of a local translator. In case
patients were illiterate and unfamiliar with the Gre-
gorian calendar, dates were estimated by correlating
the disease history of patients with local religious fes-
tivals. In Nepal, patients originating from six endemic
Terai districts (Mahottari, Siraha, Saptari, Sunsari,
Morang, Jhapa) but also from three so-called non-
endemic districts (Bhojpur, Dhankuta and Sankhuwa-
sava) were encountered and interviewed (Figure 2).
Bihar/India: Patients originating from 14 districts
(Gopalganj, Purba Champaran, Siwan, Saran, Muzaffarpur,
Vaishali, Samastipur, Nalanda, Patna, Gaya, Sheohar,
Munger, Khagaria and Madhepura) were interviewed at
local hospitals or PHCs (Figure 2). People infected with
VL but not registered as VL patients at hospitals orPHCs could not be identified as subjects of this study
which might have introduced a selection bias. To
strengthen the presented results, a follow-up study
combining the methodology of this work with ACD
could be envisioned.
Study population – health managers; Nepal
D(P)HOs/ EWARS sites of twelve Nepali districts where
VL is known to be endemic and nine DMOs/DHs/
PHCs of Bihar districts were visited and local health
managers were interviewed (Figure 2). In Nepal, these
districts are located in the eastern and central develop-
ment region of Nepal: Parsa, Bara, Rautahat, Sarlahi,
Mahottari, Dhanusha, Siraha, Saptari, Sunsari, Morang,
Jhapa and Udayapur. The following local health profes-
sionals were interviewed individually by the principal in-
vestigator: District Health Officer, Vector Control
Officer, Vector Control Inspector, Vector Control Super-
visor, Monitoring & Evaluation Officer, Medical Record
Officer, different medical personal. Bihar/India: In Bihar
VL is endemic in most districts, however there are high
endemic (northern and eastern Bihar) and low endemic
districts (southern and western Bihar). Both high en-
demic districts (Gopalganj, Purba Champaran, Siwan,
Saran, Muzaffarpur, Vaishali and Samastipur) as well as
low endemic districts (Nalanda and Jahanabad) were vis-
ited (Figure 2). The following local health professionals
were interviewed individually by the principle investiga-
tor: Civil surgeon, District Malaria Officer, Vector-borne
Disease consultant, Malaria Inspector, Kala Azar Technical
Figure 2 Districts of Nepal and Bihar included in this study. In Nepal, health managers of districts 1 to 12, 1-Parsa, 2-Bara, 3-Rautahat, 4-Sarlahi,
5-Mahottari, 6-Dhanusha, 7-Siraha, 8-Saptari, 9-Sunsari, 10-Morang, 11-Jhapa and 12-Udayapur, were interviewed. Patients interviewed resided in districts
5, 7 to 11, 13-Bhojpur, 14-Dhankuta and 15-Sankhuwasava. In Bihar, health managers of districts 1 to 9, 1-Gopalganj, 2-Purba Champaran, 3-Siwan, 4-Saran,
5-Muzaffarpur, 6-Vaishali, 7-Samastipur, 8-Nalanda, 9-Jahanabad, were interviewed. Patients interviewed resided in districts 1 to 8, 10-Patna, 11-Gaya, 12-Sheohar,
13-Munger, 14-Khagaria and 15-Madhepura.
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operator, Lab Technician, Block Health Manager. Inter-
views from mentioned district health professionals were
pooled as “health manager interviews” in both VL endemic
regions. Similarly, central level health professionals from
EDCD and State Program Office Kala Azar & Malaria were
interviewed in Kathmandu, Nepal, and in Patna, Bihar.Study sample size - patients
Based on current literature, it was hypothesized that it
takes twice as much time for a patient to receive treat-
ment after presentation to the health system in Bihar as
compared to Nepal [7]. To compare the means of both
VL endemic regions in this study, an unpaired t-test waschosen as only two groups (patients from Terai and
Bihar) were present here. Required sample sizes of pa-
tients to reject the corresponding H0 were calculated
using online study design tools available on “http://www.
biomath.info/power/ttest.htm”. The value for alpha was
set to 0.05 and power to 0.8, continuity correction was
applied. Calculated sample sizes were adjusted for a pos-
sible non-parametric data distribution requiring a non-
parametric test by increasing calculated figures by 15%
[17]. As a result, the required minimal samples size was
calculated to be 39 patients (or 39 VL episodes). The
sample size target was therefore set to approximately 50
patients or VL episodes per country. It was recorded if a
VL episode was the “first episode” or a “recurrent epi-
sode/re-infection” of a patient.
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A structured questionnaire was utilized to collect
quantitative data from patients (Additional file 1). Pa-
tients were interviewed in hospitals when receiving
treatment or at home after having completed the
treatment course. Interviews with the patients covered
the following subjects: time from feeling sick to seek-
ing health care (TP); time from seeking health care to
receiving the VL diagnosis (TD); time from diagnosis
to receiving treatment (TT); the number of consulta-
tions required for a patient before reaching the health
care provider giving treatment (NC); type of service
provider visited first (remote public service providers:
Health Posts, Sub-health Posts, Sub-centers, local
health workers, indigenous healers, local unqualified
private doctors, local pharmacists, qualified private
doctors/hospitals, government doctors/hospitals, PHCs,
self-referral to the treating hospital) and type of service
provider which referred the patient to the treating
hospital.Data collection – health managers in both study areas
A semi-structured questionnaire containing open and
closed questions was utilized to collect data from district
level health workers (Additional file 1). District health
managers were interviewed without prior notice at their
local duty station or by phone if not encountered at their
workplace. Additional information, reports and docu-
ments were collected on site and observations were re-
corded. Interviews of local health managers covered the
following subjects: reporting time and reporting fre-
quency of VL case reporting; authority to which VL
cases are reported; means of communication utilized for
reporting; practice of entering VL into a computer;
utilization of national standard formats; the status of VL
sentinel reporting in the district; personal opinion to-
wards the VL reporting speed in the country/state; pos-
sible improvements of VL reporting. A semi-structured
questionnaire was utilized to conduct in-depth inter-
views with central level health managers (Additional file
1). Central level health managers were interviewed with-
out prior notice at their duty station in the state- (in
case of Bihar) or national- (in case of Nepal) level VL re-
sponse offices. Additional information, reports and doc-
uments were collected on site and observations were
recorded. Interviews covered the following subjects: in-
formation about the VL reporting process in the coun-
try/state; means and frequency of VL reporting to the
center; reliability of the received data; possible obstacles
of electronic reporting; the status of sentinel reporting
in the country/state; personal opinion towards the VL
reporting speed in the country/state; possible improve-
ments of VL reporting.Data analysis
Data analysis was performed using the statistical soft-
ware SPSS v13 (SPSS Inc., Chicago, IL). First, the data
was tested for normal distribution using the Kolmogorov-
Smirnov normality test. As collected patient as well as
health manager data was found to be not normally distrib-
uted, differences of arithmetic means of two independent
samples were calculated using the two-tailed Mann-
Whitney U hypothesis test. In the case of patient data, dif-
ference of means was calculated for different strata, such
as countries, gender and first time and recurrent/re-
infected VL episodes of patients. To test data for differ-
ences of two proportions, Fisher's exact test was used.
Means, standard deviations and ranges have been calcu-
lated using descriptive statistics.
Ethical aspects
Ethical clearance for conducting research in Nepal was
obtained from the Nepal Health Research Council. Ethical
clearance for conducting research in Bihar was obtained
from the Ethics Committee of RMRIMS representing the
Indian Council of Medical Research. Patients were in-
formed about their rights, the implications of the inter-
view for them and then gave informed consent for
carrying out the interview.
Results
Results - patients
13 hospitals were visited in Nepal and 17 hospitals and
PHCs were visited in Bihar. In total, 92 patients having
suffered 95 VL episodes during the last 12 months were
interviewed. In Nepal, 46 patients having suffered 46 ep-
isodes of VL were identified and interviewed. In Bihar,
46 patients with 49 episodes of VL were interviewed.
TD was found to be very high in Bihar (90 days, SEM=
11.1) where different private and public treatment options
were available; TP and TT of Bihar were only 8 (SEM=
1.9) and 6 days (SEM= 1.6), respectively (Table 1). In con-
trast, in Nepal, where travel conditions are difficult, TP
was significantly higher with 30 days (SEM= 6.0; p <
0.001) but once they get there diagnostic and treatment fa-
cilities are offered relatively fast: TD was 25 days (signifi-
cantly lower than in Bihar; SEM = 6.2; p < 0.001), and TT
was only 3 days (SEM= 1.0), which again was significantly
shorter than in Bihar (p < 0.001). The total time a patient
requires from feeling sick to receiving treatment (TTotal)
was approximately two times higher in Bihar compared to
Nepal (104 days versus 58 days). The medians of identified
lag times were lower than the means but also indicated
strong differences between Bihar and Nepal (Table 1).
There were no significant differences of means between
men and woman for TP or TT (Table 1) but women
needed a longer time to get to a VL diagnosis than men.
Means of TD of men (47 days, SEM= 7.4) and of women
Table 1 Lag times of Bihari and Nepali VL patients before receiving treatment
Time from feeling sick to seeking health care (TP)
Total Bihar Nepal Male Female First episode Recurrent episode
N 95 49 46 60 35 87 8
Mean (days) 18,62 7,59 30,37 17,95 19,77 19,23 12,75
95% Confidence Int. 12.2-25.1 3.8-11.9 18.4-42.4 10.5-25.4 7.3-32.3 12.0-26.5 4.7-20.8
Std. Error (SEM) 3.25 1.89 5.97 3.73 6.15 3.66 3.34
Std. Deviation (SD) 31,68 13,18 40,46 28,91 36,36 33,31 9,60
Kolmogorov-Smirnov p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p = 0.20
Mann-Whitney U-Test p < 0.001 p = 0.626 p = 0,677
Median (days) 8 5 15 7,5 10 8 12
Interquartile range 11 7 23 11 26 11 16
Full range 209 89 207 149 209 209 27
Time from seeking health care to receiving the VL diagnosis (TD)
Total Bihar Nepal Male Female First episode Recurrent episode
N 95 49 46 60 35 87 8
Mean (days) 58,76 90,33 25,13 47,13 78,69 57,30 57,63
95% Confidence Int. 44.4-73.1 68.1-112.6 12.7-37.6 32.4-61.8 48.9-108.5 41.7-72.9 6-4-108.8
Std. Error (SEM) 7.24 11.08 6.17 7.35 14.65 7.83 21.65
Std. Deviation (SD) 70,59 77,57 41,84 56,92 86,66 71,36 61,23
Kolmogorov-Smirnov p < 0.01 p < 0.01 p < 0.01 p < 0.01 p = 0.02 p < 0.01 p = 0.05
Mann-Whitney U-Test p < 0.001 p = 0.094 p = 0.968
Median (days) 32 67 9 30 34 30 42
Interquartile range 71 92 24 57 105 66 101
Full range 364 363 194 247 364 364 161
Time from diagnosis to receiving treatment (TT)
Total Bihar Nepal Male Female First episode Recurrent episode
N 91 48 43 58 33 83 8
Mean (days) 4,63 6,17 2,91 4,97 4,03 4,81 2,75
95% Confidence Int. 2.7-6.5 3.0-9.3 1.0-4.8 2.2-7.8 2.1-5.9 2.8-6.9 0.2-5.3
Std. Error (SEM) 0.95 1.56 0.95 1.40 0.93 1.03 1.07
Std. Deviation (SD) 9,05 10,80 6,24 10,62 5,34 9,42 3,01
Kolmogorov-Smirnov p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Mann-Whitney U-Test p < 0.001 p = 0.714 p = 0.868
Median (days) 5 2 1 1 1 1 1,5
Interquartile range 4 7 3 4 6 4 5
Full range 55 54 37 55 23 55 8
Time from feeling sick to seeking health care (TP), time from seeking health care to receiving the VL diagnosis (TD) and time from diagnosis to receiving treatment
(TT). Data is given as total as well as stratified by nationality, sex and VL history.
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statistically not significant (p = 0.094, Table 1). There
was no significant difference of lag times for TP be-
tween first time and recurrent/ re-infected VL episodes
of patients.
When analyzing the number of consultations required
for a patient before reaching the health care provider
(NC), the average NC for VL patients of both countrieswas found to be 2.0 consultations (SEM = 0.2, Table 2).
There was no significant difference between men and
woman as well as first time and recurrent/ re-infected
VL episodes of patients. However, the number of consul-
tations (“doctor shopping”) before reaching the PHC
was significantly higher in Bihar (2.6 consultations,
SEM = 0.2) than in Nepal (1.4 consultation, SEM = 0.2;
p < 0.001).
Table 2 Number of health consultations of VL patients before reaching the treatment hospital/PHC
Number of consultations before arriving in treating hospital/PHC
Total Bihar Nepal Male Female First episode Recurrent episode
N 95 49 46 60 35 87 8
Mean (consultations) 2,0 2,6 1,4 1,9 2,1 2,0 1,6
95% Confidence Int. 1.7-2.3 2.2-3.0 1.1-1.7 1.6-2.3 1.6-2.7 1.7-2.3 0.5-2.7
Std. Error (SEM) 0.15 0.21 0.16 0.17 0.27 0.15 0.46
Std. Deviation (SD) 1,4 1,5 1,1 1,7 1,6 1,4 1,3
Kolmogorov-Smirnov p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p = 0.114
Mann-Whitney U-Test p < 0.001 p = 0.631 p = 0.530
Median 2 2 1 2 2 2 2
Interquartile range 2 2 1 2 2 2 2
Full range 7 7 4 6 7 7 4
Data is given as total as well as stratified by nationality, sex and VL history.
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qualified private healer (“doctor”), 24% a qualified private
doctor and 4% a government doctor/hospital (Figure 3). In
Nepal, 33% of patients visited initially a local unqualified
private healer (“doctor”), 15% a qualified private doctor,
22% the treating hospital, 15% a government doctor/hos-
pital and 11% a remote health worker. The impact of these
initial choices of a service provider on the time from seek-
ing health care to receiving the VL diagnosis particularly
in Bihar has been mentioned above when presenting the
TD data (Table 3). In Bihar, TD was significantly higher
when patients first visited a local unqualified private healer
(“doctor”) (95 days, SEM= 12.0; p = 0.003) or a qualified
private doctor (90 days, SEM= 27.6; p = 0.044) as opposed
to a government doctor/hospital (4 days, SEM= 2.0).
There was no significant difference of TD between visitingFigure 3 Health care providers consulted first by Bihari and Nepali VLa qualified or an unqualified private doctor first (p =
0.600). In Nepal too, no significant difference of TD could
be detected between visiting a qualified or an unqualified
private doctor first (p = 0.630).
Results - health managers
In Nepal, one to three health managers of all twelve VL
endemic districts were interviewed, in total 29 persons.
However, since health managers of the same office gave
the same information, only one interview was considered
for analysis, resulting in a total of twelve qualitatively
different interviews from D(P)HOs and ten from
EWARS sites. In Bihar, one to three health managers
per district were interviewed, in total 20 persons. Nine
interviews were conducted with health managers of
DMOs, ten interviews with health managers of DHs/PHCspatients.
Table 3 Impact of choice of health care providers consulted first on TD
Bihar - time from seeking health care to receiving the VL diagnosis (TD)


















N 49 0 0 35 12 2 0
Mean (days) 90,33 95.46 89.75 4.00
95% Confidence Int. 68.1-112.6 71.0-119.9 29.0-150.5 -21.4-29.4
Std. Error (SEM) 11.08 12.03 27.62 2.00
Std. Deviation (SD) 77,57 71.18 95.68 2.83
Kolmogorov-Smirn. p < 0.01 p = 0.03 p < 0.01 P = 0.26
Median (days) 67 75 67 4
Interquartile range 92 102 60 -
Full range 363 239 361 4
Mann-Whitney U-Test: Local unqualified/Qualified private p = 0.600
Mann-Whitney U-Test: Local unqualified/Government hospital p = 0.003
Mann-Whitney U-Test: Qualified private/Government hospital p = 0.044
Nepal - time from seeking health care to receiving the VL diagnosis (TD)


















N 46 5 2 15 7 7 10
Mean (days) 25,13 48,00 50,00 25,73 46,29 11,43 2,60
95% Confidence Int. 12.7-37.6 -9.1-105.1 -343.8-444 1.5-50.0 -16.4-109.0 2.72-20.13 1.0-4.2
Std. Error (SEM) 6.17 20.57 31.00 11.31 25.62 3.56 0.70
Std. Deviation (SD) 41,84 45,99 43,84 43,81 67,77 9,41 2,22
Kolmogorov-Smirn. p < 0.01 p = 0.2 p < 0.01 p < 0.01 p = 0.12 p < 0.01
Median (days) 9 30 50 11 30 8 2
Interquartile range 24 85 - 16 39 18 3
Full range 194 109 62 174 193 25 7
Mann-Whitney U-Test: Local unqualified/Qualified private p = 0.630
Mann-Whitney U-Test: Local unqualified/Government hospital p = 0.210
Mann-Whitney U-Test : Qualified private/Government hospital p = 0.259
Total - time from seeking health care to receiving the VL diagnosis (TD)


















N 95 5 2 50 19 9 10
Mean (days) 58,76 48.00 50.00 74.54 73.74 9.78 2.60
95% Confidence Int. 44.4-73.1 -9.1-105.1 -343.8-444 54.2-94.9 31.8-115.7 3.0-16.6 1.0-4.2
Std. Error (SEM) 7.24 20.57 31.00 10.11 19,99 2.95 0.70
Std. Deviation (SD) 70,59 45.99 43.84 71.46 87.12 8.84 2.22
Kolmogorov-Smirn. p < 0.01 p = 0.20 p < 0.01 p < 0.01 p = 0.062 p < 0.01
Median (days) 32 30 50 53 43 7 2
Interquartile range 71 85 - 94 53 13 3
Full range 364 109 62 243 363 25 7
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Table 3 Impact of choice of health care providers consulted first on TD (Continued)
Mann-Whitney U-Test: Local unqualified/Qualified private p = 0.752
Mann-Whitney U-Test: Local unqualified/Government hospital p < 0.001
Mann-Whitney U-Test: Qualified private/Government hospital p = 0.002
Data is given as total as well as stratified by service providers consulted first.
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Surveillance Project (IDSP).
In depth discussions in Nepal revealed that two differ-
ent types of district-level health authorities report to the
central level: District Public Health Offices (D(P)HOs)
and Early Warning and Reporting System (EWARS) sen-
tinel sites (usually located in zonal/district hospitals).
EWARS sentinel sites are expected to report weekly to
an EWARS focal person within the Epidemiology and
Disease Control Division (EDCD), whereas D(P)HOs are
expected to report monthly directly to the vector-borne
disease department of the EDCD. Only 8% of health
managers working in D(P)HOs knew about the VL senti-
nel function of an EWARS site (Table 4). In Bihar, only
DMOs are expected to report monthly from the district
to the State authority, State Program Office Kala Azar
(SPOKA) in Patna, but no VL sentinel sites were identi-
fied. SPOKA compiles all reports and forwards them
each month to National Vector Borne Disease Control
Program (NVBDCP) in Delhi.
All DMOs and all D(P)HOs were found to report to
the respective central level authority, whereas only 90%
of EWARS sites did so. The actual reporting speed was
found to be in Nepal 2.7 weeks for EWARS sites (SEM=
1.7), 10.8 weeks for D(P)HOs (SEM= 1.9), and in Bihar
4.0 weeks for DMOs 4.0 (SEM= 0) (Table 5). Inter-
quartile and full range analysis reveals a high variance for
D(P)HOs reporting speeds which is not true for EWARS
sites and DMOs (Table 5). District level health authorities
were found not only to report to their directly correspond-
ing central level VL authority, but also to a multiplicity of
different offices. In Bihar, all DMOs also reported to IDSP,
78% to the Regional Health Directorate and 78% directly
to the national authority NVBDCP. In Nepal, all D(P)HOsTable 4 Cross tabulation of KAP regarding VL reporting of di
VL cases are entered into a computer by the health worker/manager
National standard formats are used for VL case reporting to concerned cente
authorities
VL Sentinel Sites are known to health managersalso report to Health Management Information System
(HMIS), 58% to the Regional Health Directorate, 17% to
the Vector Borne Disease Research and Training Center
(VBDRTC) and 8% directly to the state WHO office. 90%
of EWARS sites reported to HMIS, 60% to the Regional
Health Directorate and 20% to the VBDRTC.
District-level health offices of both countries mainly
used mail for the data transfer to the central level or
they sent messengers, D(P)HOs in Nepal additionally
used fax (Figure 4). In Nepal 80% of EWARS sites and
50% of D(P)HOs were equipped with email facilities,
whereas DMOs in Bihar did not have computers or
internet access. In Nepal, 73% of D(P)HO health man-
agers in district facilities entered VL data in a computer
file, whereas in Bihar only 16% of DMO health man-
agers were able to do so. Surprisingly, all PHCs in Bihar
had computers, internet access and email facilities and
used online database systems for HMIS reporting but
not for VL which was not included in the HMIS pack-
age. Due to this situation VL reports from PHCs to
DMOs are still done by hand. In both countries VL
reporting formats to be used in the district health offices
contained similar information but were not standardized
within the countries. Only 8% of D(P)HOs in Nepal
were using a standard reporting format defined in the
national VL elimination guidelines whereas the rest pre-
ferred to use their own case report formats with varying
information (Table 4, Additional file 2: Figure S1). In
contrast, EWARS sites used the national standard for-
mat which was available either as hard copy or as a MS
Excel table. The same situation in Bihar: DMOs did not
use a national standard format for reporting to SPOKA
but had their own VL case reporting format. This was
done mostly by hand and contained only limitedstrict health managers in Bihar and Nepal
Office/facility of local health
managers
N Yes No Fisher's exact
test
Bihar - all facilities 19 3 16 p < 0.001
Nepal - all facilities 22 16 6
r D(P)HOs - Nepal 12 1 11 p = 1.000
DMOs - Bihar 9 0 9
EWARS sites -Nepal 10 9 1 p < 0.001
D(P)HOs - Nepal 12 1 11
Table 5 VL reporting speed of Bihari and Nepali district health managers to the respective state or national health
authority
EWARS sites - Nepal D(P)HOs - Nepal DMOs - Bihar
N 9 12 9
Mean (weeks) 2,7 10,8 4
95% Confidence Int. 1.2-6.5 6.6-14.9
Std. Error (SEM) 1.7 1.9 0
Std. Deviation (SD) 5,0 6,5 0
Kolmogorov-Smirnov p < 0.01 p < 0.01 p < 0.01
Median 1 16 4
Interquartile range 0 12 0
Full range 15 15 0
Mann-Whitney U-Test: EWARS sites -Nepal/D(P)HOs - Nepal p = 0.002
Mann-Whitney U-Test: D(P)HOs – Nepal/DMOs - Bihar p = 0.024
Mann-Whitney U-Test: EWARS sites/DMOs - Bihar p = 0.002
Data is given as total as well as stratified by type of district health authority.
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and PKDL cases (Table 4, Additional file 2: Figure S1).Discussion
This study identified three different major lag times VL
patients face when seeking treatment in Terai, Nepal,
and Bihar, India. In Bihar, the time from seeking health
care to receiving a VL diagnosis is alarmingly high (90
days). In Nepal, patients who feel sick wait too long be-
fore seeking health care (30 days). In addition, VL
reporting times of district health managers in Bihar and
Nepal was recorded for the first time: in Nepal, in tookFigure 4 Availability of means of communication for VL reporting at19 days to report a VL case and in Bihar it took 28 days.
For both VL endemic regions, the results of this study
can be depicted as a continuous timeline from the on-
set of symptoms of a VL patient until this patient’s case
is reported to the center (Figure 5). In Nepal, this period
consumes 77 days, whereas in Bihar 132 days are
expended.
The VL elimination strategy is built on five pillars [11]
two of which are closely linked to this study: “Early diag-
nosis and complete treatment of cases” and “Effective
disease surveillance through passive and active case de-
tection”. Early diagnosis and immediate treatment are
not only important for individual patients to cut downdistrict level.
Figure 5 Timeline from on-set of symptoms of a patient until this patient’s case is reported to the center. The average time from feeling
sick to seeking health care (TP), from seeking health care to receiving the VL diagnosis (TD), from diagnosis to receiving treatment (TT) and for
case reporting from district to center (TR) is given in days. VL reporting speed of EWARS sentinel sites is depicted for Nepal.
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fected humans serve as parasite reservoir and sources of
infection [18]. VL reporting by local health managers
from the district level to the central level is the back-
bone of VL surveillance and subsequent ACD activities.
In this study, the lag time from feeling sick to seeking
health care (TP) and the lag time from seeking health
care to receiving the VL diagnosis (TD) were identified
to be major obstacles to early diagnosis and treatment.
TD, the time from initiating the search for help after feel-
ing sick to reaching a proper diagnosis, was particularly
long in Bihar (90 days) where “doctor shopping”, i.e. the
use of a variety of different informal and formal health
care providers, was common. In contrast, in Nepal, with
its limited access to health services, the decision to go
for help after feeling sick (TP) was delayed leading to a
prolonged infective period of patients [19,20]. This situ-
ation is unchanged in Nepal but clearly improved in
Bihar compared to a previous study 4 years before our
study in Bihar, Nepal and Bangladesh [7]. The observa-
tion that Bihari VL patients seem to seek health care
and visit a service provider earlier than in 2008 may
have the following reasons: Educational efforts about VL
within the community might have been successful to the
extent that the population knows at least about the
socio-economic consequences of VL as well as about VL
symptoms and its mode of transmission [21,22] and
health services are now more accessible in Bihar [23]. In
Nepal, road conditions and accessibility of health ser-
vices continue to be an issue in the VL endemic areas
and the incentive of 1000 rupees might need to be raised
in order to attract more patients to visit governmentTable 6 Cross tabulation of Bihari and Nepali VL patients faci
Time from feeling sick to seeking health care (TP) exceeds two weeks
Time from seeking health care to receiving the VL diagnosis (TD) exceeds tw
Time from diagnosis to receiving treatment (TT) exceeds two weeks
Results of Fisher’s exact significance tests are given in the table.facilities. The previous study additionally found TD to
exceed one week in 42% of cases of a combined sample
of 113 patients from Bihar, Nepal and Bangladesh [7],
compared to 79% in our study. Although the methods
and places of the study were different, lag times and thus
the period of infectivity continue to be a serious problem
and seem to have even deteriorated. In Bihar, 95% of pa-
tients preferred to visit a private provider first whereas
only 4% chose to visit a government doctor. In 2003,
11.39% of patients were found to prefer the public sector
in Bihar [4], indicating that the acceptance for public
service providers has not increased in Bihar since nine
years. TD was significantly higher for patients initially
visiting a private service provider as compared to pa-
tients visiting a government doctor or hospital. To en-
courage referrals to the public sector, private providers
could receive a financial bonus when referring VL pa-
tients to a government hospital. Furthermore, “doctor
shopping” and extensive utilization of the private sector
could be reduced by providing IEC about VL services of
the public sector in Bihar. Also, increasing ACD could
help identifying patients not self-reporting to or drop-
ping out of the health system which would decrease TP
as well as TD.
The time between diagnosis and start of treatment (TT)
was small in both countries reflecting the increased avail-
ability of miltefosine in local treatment centers [24,25].
These figures represent a major advance compared to the
study in 2008 when 36% of patients in Nepal, Bihar and
Bangladesh had to wait for more than two weeks after the
diagnosis for the start of treatment [7] while in our study
these were only 6% in Bihar and 7% in Nepal (Table 6).ng times of two weeks or more for TP, TD and TT
Country N Yes No Fisher's exact test
Bihar 49 6 43 p < 0.001
Nepal 46 24 22
o weeks Bihar 49 43 6 p < 0.001
Nepal 46 16 30
Bihar 48 3 45 p = 1.000
Nepal 43 3 40
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VL for the first time and patients suffering a recurrent
infection/re-infection were the same. This is surprising,
as patients might know better how to react properly to
VL symptoms when experiencing them a second time.
However, patients stated that they assumed to be suc-
cessfully cured and that they could not be infected with
VL again indicating a lack of information about the pos-
sibility of a VL recurrence or re-infection. Women
tended to have a longer period of looking for care before
receiving a VL diagnosis. Although the differences were
not statistically significant, these preliminary findings co-
incide with previously reported findings and general
gender-based health inequalities in South Asian coun-
tries [12,26,27].
VL reporting is a main focus of VL elimination activ-
ities which include training of health managers, revision
of reporting formats and employment of additional staff.
This study presents first data on implementation and
functionality of VL reporting from the district to the
center in the region in Nepal and Bihar. Only DMOs in
Bihar were able to reach the target to report to the cen-
ter within four weeks. D(P)HOs in Nepal required sig-
nificantly longer times to report to the center (10.8
weeks) as health managers send reports at varying times:
sometimes weekly, or every four weeks (following the
new national standard of 4 weeks instead of 16 weeks)
or every 16 weeks. Data reported by D(P)HOs is cur-
rently of lower importance for central level health man-
agers in Nepal, as faster and more reliable alternatives
like EWARS sentinel reporting and HMIS already exist.
EWARS sites are widely distributed in Nepal and report
directly to an own department in EDCD [15]. They
cover six infectious diseases including VL, function simi-
larly to specialized VL sentinel sites -as proposed by the
VL elimination strategy-, are hospital-based and have to
report weekly to the center [9,28]. Interestingly, at the
time of our study, 90% of health managers working in
D(P)HOs did not know about EWARS sites functioning as
VL sentinel sites. HMIS data is collected in all D(P)HOs
and hospitals of the country and reported monthly to the
HMIS department of the Department of Health Services.
EDCD receives a copy of HMIS reports containing VL
data.
In Bihar, no sentinel VL reporting sites were identified.
DMOs do not report to HMIS and VL cases are not in-
cluded in standard HMIS reporting from PHCs or DHs.
Furthermore, SPOKA does not receive any VL-related
information from the state or national HMIS authority.
This separation of the modern, online-based HMIS sys-
tem and the paper-based VL reporting is surprising be-
cause WHO proposed to increase the linkage of VL
reporting with HMIS already in 2006 [28]. This separ-
ation is evident down to the sub-district level: all PHCswere found to be equipped with computers and internet
access to report to HMIS online. However, the available
HMIS infrastructure on sub-district level cannot be uti-
lized for VL reporting due to information technology
shortcomings on the district (DMOs) and state level
(SPOKA). It is now essential for center level health man-
agers in India to closely link HMIS and VL reporting to
be able to utilize these resources. In Nepal, D(P)HOs
and HMIS are better connected and EDCD incorporates
data obtained from HMIS. However, D(P)HO reporting
is mainly paper-based too and email was rarely used. In
both countries no appliance of national standard VL
reporting formats was observed, instead individually de-
signed and often hand-written reporting formats were
utilized which represents a major problem for data reli-
ability. As reported previously, observed formats did not
permit to monitor patient adherence and clinical out-
comes [29]. Furthermore, analyzing the collected data
and reporting concisely and timely is very difficult to do
for DMOs without a computer. To standardize VL
reporting and monitor clinical outcomes in both coun-
tries it is now important to introduce one joint elec-
tronic reporting system using the existing computer
infrastructure and mobile smart phones.
In both countries district health managers do not only
report according to the standard hierarchical way of
their country but also to a multitude of other govern-
mental offices/agencies. This reporting can be relevant
for the district or region (e.g. reporting to Civil surgeons,
Additional Chief Medical Officers, and Regional Health
Directorates) but can also be irrelevant because the re-
cipient simply ignores the reports. However, although
additional reporting often does not initiate direct actions
of local decision makers it might increase awareness to-
wards VL.Conclusions
The study highlights long delay times in Nepal and
Bihar/India which patients are facing when seeking VL
diagnosis and treatment as well as extended reporting
times within the national VL reporting systems. It re-
quires on average 132 days in Bihar and 77 days in
Nepal from the on-set of symptoms until this patient’s
case is reported to the center. This study raises issues
of possible wrong diagnosis by private health care
providers, the underutilization of computers for VL
reporting and the lack of VL sentinel reporting sites in
Bihar. It encourages central level health managers in
Nepal and Bihar to implement an electronic VL
reporting system and closely link it with HMIS. It calls
for a public-private partnership for VL diagnostic in
Bihar to reduce delays for patients and reduce transmis-
sion of the disease.
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